^
    7d
    NRG-GY031: Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer (clinicaltrials.gov)
    P1, N=65, Recruiting, National Cancer Institute (NCI) | Trial completion date: Apr 2026 --> Jun 2027 | Trial primary completion date: Apr 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    MSI (Microsatellite instability) • ARID1A (AT-rich interaction domain 1A)
    |
    MSI-H/dMMR
    |
    ZEN-3694 • tuvusertib (M1774)
    8d
    Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer (clinicaltrials.gov)
    P1, N=74, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2026 --> Jun 2027
    Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2) • ER (Estrogen receptor) • PGR (Progesterone receptor)
    |
    HER-2 negative
    |
    cisplatin • gemcitabine • elimusertib (BAY 1895344)
    14d
    Transient ATR inhibition following ionizing radiation enhances immune-mediated antitumor response and survival. (PubMed, bioRxiv)
    In vivo and in vitro studies have shown enhanced tumor cell radiosensitivity with the ATRi ceralasertib, elimusertib, and berzosertib, however, the potentiating effect of ATRi on ionizing radiation (IR) through immune-based mechanisms has only been studied with ceralasertib. ATRi elicited differential inflammatory gene induction and dose-dependent unique cytotoxicity profiles in vitro . The immune mediated antitumor effect of ATRi combined with radiation is dose and schedule dependent, and while likely a class effect, may differ between ATRi compounds.
    Journal
    |
    CD8 (cluster of differentiation 8)
    |
    berzosertib (M6620) • ceralasertib (AZD6738) • elimusertib (BAY 1895344)
    16d
    Testing the Addition of an Anti-Cancer Drug, Camonsertib, to Radiation Therapy for Recurrent Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=39, Recruiting, National Cancer Institute (NCI) | Initiation date: Jun 2026 --> Feb 2027 | Not yet recruiting --> Recruiting
    Enrollment open • Trial initiation date • Tumor mutational burden
    |
    camonsertib (RP-3500)
    16d
    Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) (clinicaltrials.gov)
    P2, N=63, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial primary completion date: Sep 2025 --> Jun 2026
    Trial primary completion date
    |
    BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • HRD (Homologous Recombination Deficiency)
    |
    BRCA1 mutation • HRD
    |
    Zejula (niraparib) • tuvusertib (M1774) • lartesertib (M4076)
    17d
    Integrative analysis of lncRNAs associated with disulfidptosis-related genes for prognostic risk evaluation and tumor immune microenvironment assessment in laryngeal squamous cell carcinoma. (PubMed, Hum Cell)
    Exploratory in silico drug-response analyses identified differential predicted responses to entinostat, linsitinib, and VE-822 according to risk status and DUBR expression. This internally validated signature may support exploratory prognostic risk stratification of LSCC within the analyzed TCGA-derived cohort and may highlight DUBR as a candidate molecule for further biological investigation. Further validation in independent external cohorts and dedicated disulfidptosis functional assays is required before these findings can be considered generalizable.
    Journal
    |
    TLN1 (Talin 1) • METTL3 (Methyltransferase Like 3)
    |
    berzosertib (M6620) • Jingzhuda (entinostat) • linsitinib (ASP7487)
    17d
    ATRN-119 in Combination With Decitabine in Patients With TP53-Mutated AML or Higher-Risk MDS (clinicaltrials.gov)
    P1, N=27, Not yet recruiting, Washington University School of Medicine
    New P1 trial
    |
    TP53 (Tumor protein P53)
    |
    TP53 mutation
    |
    decitabine • ATRN-119
    18d
    Ceralasertib Monotherapy in Patients with ATM-Altered Advanced Solid Tumors or Metastatic Castration-Resistant Prostate Cancer: Data from the Phase 2a PLANETTE Study. (PubMed, Cancer Res Commun)
    Ceralasertib monotherapy was tolerated; however, responses were limited. Alternative patient selection and combination treatments are being explored.
    P2a data • Journal
    |
    ATM (ATM serine/threonine kinase)
    |
    ceralasertib (AZD6738)
    22d
    Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320) (clinicaltrials.gov)
    P1, N=120, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Apr 2026 --> Jan 2027 | Trial primary completion date: Apr 2026 --> Jan 2027
    Trial completion date • Trial primary completion date • Checkpoint inhibition • IO biomarker
    |
    ATM (ATM serine/threonine kinase) • ARID1A (AT-rich interaction domain 1A)
    |
    ARID1A mutation
    |
    Bavencio (avelumab) • tuvusertib (M1774) • lartesertib (M4076)
    22d
    Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) (clinicaltrials.gov)
    P1/2, N=61, Active, not recruiting, EMD Serono Research & Development Institute, Inc. | Trial completion date: Mar 2026 --> Sep 2026 | Trial primary completion date: Mar 2026 --> Sep 2026
    Trial completion date • Trial primary completion date
    |
    Libtayo (cemiplimab-rwlc) • tuvusertib (M1774)
    23d
    Radiosensitisation of Head and Neck Cancer Cells to Protons of Increasing LET Through Targeting DNA Double Strand Break Repair. (PubMed, Cells)
    We demonstrate that inhibitors against ATR (AZD6738), and particularly ATM (AZD1390) and DNA-Pkcs (AZD7648), could significantly decrease clonogenic survival of HNSCC cell lines following PBT at both low and relatively high LET (~2 keV/µm and ~8 keV/µm, respectively). We confirmed that the inhibitors in combination with PBT led to DSB persistence through neutral comet assays and monitoring γH2AX/53BP1 foci. We also show that this strategy can enhance the sensitivity of patient-derived organoids of HNSCC to PBT of both low and high LET, highlighting this as a strategy which should be exploited further.
    Journal
    |
    ATR (Ataxia telangiectasia and Rad3-related protein) • TP53BP1 (Tumor Protein P53 Binding Protein 1)
    |
    ceralasertib (AZD6738) • AZD1390 • AZD7648
    1m
    ETCTN 10402: Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic Cancer (clinicaltrials.gov)
    P1, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Mar 2026 --> Mar 2027
    Trial completion date
    |
    irinotecan • topotecan • elimusertib (BAY 1895344)